Geode Capital Management’s Cardiol Therapeutics CRDL Stock Holding History

Geode Capital Management’s Portfolio CRDL Stock Details CRDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$44.7K	Sell	42,196 -10,239	-20%	-$13K	﹤0.01%	4266
2026 Q1	$70.8K	Hold	52,435	–	–	﹤0.01%	4229
2025 Q4	$50K	Hold	52,435	–	–	﹤0.01%	4233
2025 Q3	$56.1K	Hold	52,435	–	–	﹤0.01%	4267
2025 Q2	$71.3K	Hold	52,435	–	–	﹤0.01%	4152
2025 Q1	$50.9K	Hold	52,435	–	–	﹤0.01%	4196
2024 Q4	$67.1K	Hold	52,435	–	–	﹤0.01%	4189
2024 Q3	$104K	Hold	52,435	–	–	﹤0.01%	4092
2024 Q2	$106K	Hold	52,435	–	–	﹤0.01%	4123
2024 Q1	$94.9K	Hold	52,435	–	–	﹤0.01%	4173
2023 Q4	$44K	Hold	52,435	–	–	﹤0.01%	4382
2023 Q3	$48.2K	Hold	52,435	–	–	﹤0.01%	4427
2023 Q2	$46.7K	Hold	52,435	–	–	﹤0.01%	4518
2023 Q1	$25.6K	Hold	52,435	–	–	﹤0.01%	4659
2022 Q4	$26K	Hold	52,435	–	–	﹤0.01%	4726
2022 Q3	$54K	Hold	52,435	–	–	﹤0.01%	4750
2022 Q2	$69K	Hold	52,435	–	–	﹤0.01%	4697
2022 Q1	$80K	Hold	52,435	–	–	﹤0.01%	4713
2021 Q4	$97K	Hold	52,435	–	–	﹤0.01%	4744
2021 Q3	$217K	Buy	+52,435	New	+$190K	﹤0.01%	4415

Other funds holding CRDL

MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return

Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Integrity Alliance Urbandale, Iowa $3.2B AUM 23.28% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management's CRDL Position: Q2 2026 in Review

Geode Capital Management reduced its Cardiol Therapeutics (CRDL) stake by 20% in Q2 2026, selling an estimated $13K and leaving 42,196 shares worth $44.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4266.

Geode Capital Management first reported a position in CRDL in Q3 2021 and has held it in 20 quarters since. The position peaked at $217K in Q3 2021. 52 funds tracked by Wall St. Rank hold CRDL as of Q2 2026.

Geode Capital Management held 42,196 shares of Cardiol Therapeutics worth $44.7K as of Q2 2026.
Geode Capital Management sold 10,239 Cardiol Therapeutics shares in Q2 2026, an estimated $13K.
Cardiol Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #4266 holding.
Geode Capital Management first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 20 quarters since.
Geode Capital Management's Cardiol Therapeutics position peaked at $217K in Q3 2021.
52 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.